GCC Secretary-General Meets with Minister of State for Foreign Affairs of Bangladesh at Davos Forum    Saudi physics team wins 3 global awards in 2022 European Olympiad    SDRPY launches project to rehabilitate Haijat Al-Abed road    KSrelief Conducts 300 Surgeries as Part of Voluntary Medical Project to Combat Blindness in Al-Mukalla    SAMA governor, CMA chairman thank Saudi leadership for approving FinTech strategy    NDMC Closes the May 2022 Issuance under Saudi Arabian Government SAR-denominated Sukuk Program    Crown Prince discusses relations with members of US Congress    SFDA warns against Jif peanut butter products    KSrelief Participates in High-Level Regional Meeting on Youth    Women's green futsal team wins bronze in Gulf Games    Saudi Stock Exchange Main Index Ends Trading Higher at 12,300.86 Points    Cabinet to continue implementing initiatives and reforms to achieve Vision 2030 objectives    DCO, WEF launch initiative to boost global digital FDI flows    Uganda Supports Saudi Arabia's Bid to Host World Expo 2030    Aramco can't expand output capacity any faster, says CEO Amin Nasser warns of oil crunch    Consensus needed over digital technology for 'people and the planet'    International community urged to support new administration in Somalia    Global jobs market recovery 'has gone into reverse', warns UN labor agency    Saudi Press: Saudi Arabia Exerts Exceptional Efforts to Achieve Security and Stability in Yemen    Appeals court affirms termination of Wafa Insurance's financial restructuring    Saudi Vice Minister of Defense Visits CENTCOM Headquarters    In a Report to SPA .. SDAIA: Autonomous Vehicles Will Be Commercially Available in World by 2030, Will Account for 50% of Sales after 2045    Manchester City clinches Premier League title on dramatic final day    How Syrian singer Rasha Rizk dazzled millennials at Jeddah Season?    King Salman Park begins construction on its Royal Arts Complex    Shoura members propose equal blood money for men and women, Muslim and non-Muslim    KSrelief's Masam Project Dismantles 1,339 Mines within a Week in Yemen    British Investors Express Interest in Investing in Saudi Arabia's Food, Drug Market    7 Die in Philippine Ferry Fire; over 120 Rescued from Water    Ithra Participates in Cannes Film Festival with New Films to Support Saudi Talents    Exclusive launching of Michael Schumacher Digital Experience at Jeddah F1 Grand Prix    MoH allows 6 categories to receive second booster dose    Mbappé signs new 3-year PSG deal after rejecting Real Madrid    Saudi Aramco: London Championship to Witness Participation of World's Best Female Golfers    Saudi woman finds out she is male after 20 years    Saudi Arabia Heads to Cannes International Film Festival to Promote Country's Flourishing Industry and Support Emerging Talent on World Stage    President of SAFF Participates in AFC General Assembly Meeting    Saudi Athletes Achieve Great Victories in the 2nd Day of the GCC Games Tournament in Kuwait    Jazan Hosts West Asian Beach Soccer Championship    Bollywood actor's tweet reignited debate over Hindi as India's national language    SFDA Advises to Wash Dates Well Before Eating    SFDA Advises Against Mixing Surplus of Iftar and Suhoor with Different Foods or Surplus from Other Days    Ministry calls on imams to avoid long supplications in Tahajjud Prayer    Nothing wrong with a Muslim celebrating birthdays, says Saudi scholar    Custodian of the Two Holy Mosques addresses citizens and all Muslims on the occasion of the Holy month of Ramadan    Pilgrims Perform Dhuhr and Asr Prayers at Arafat Holy Site    Council of Senior Scholars: Muslim Brothers' Group Don't Represent Method of Islam, rather only Follows its Partisan Objectives, Violating our Graceful Religion    Eid Al-Adha Prayer Performed at the Grand Holy Mosque    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



Moderna to seek approval for its COVID-19 vaccine in Europe and US
Published in The Saudi Gazette on 30 - 11 - 2020

Biotech company Moderna said it will on Monday ask for approval of its COVID-19 vaccine in both Europe and the US.
The firm made the announcement as it revealed that final trial results showed its vaccine was 94.1% effective. Moderna said the vaccine was 100% effective against severe COVID-19.
The company will file for conditional approval from the European Medicines Agency and for an emergency use authorization from the US Food and Drug Administration.
"This positive primary analysis confirms the ability of our vaccine to prevent COVID-19 disease with 94.1% efficacy and importantly, the ability to prevent severe COVID-19 disease," said Stéphane Bancel, chief executive officer of Moderna.
"We believe that our vaccine will provide a new and powerful tool that may change the course of this pandemic and help prevent severe disease, hospitalizations and death," he continued.
It came after results showed that 196 of the 30,000 participants in the Moderna trials contracted COVID-19. Just 11 of those cases were among people who received the Moderna candidate vaccine.
They build on Moderna's previously reported findings, based on a smaller number of cases detected in its study of some 30,000 volunteers.
"There were 30 cases on placebo and zero cases that were on the vaccine," said Dr. Stephen Hoge, the president of Moderna. "So, it looks like in the trial we've been 100 percent effective at preventing severe COVID-19, which is really what's driving the burden of disease in hospitals and ultimately straining our public health systems."
Pfizer applied for emergency use authorization on Nov. 9 for its COVID-19 vaccine. The FDA will hold its advisory committee to discuss that application on Dec. 10. That meeting is open to the public.
The FDA's charge is to assure that drugs are both safe and effective and the agency says it is not cutting corners when it comes to COVID-19 vaccines, which after all, will potentially be given to many millions of healthy people.
Moderna expects that on Dec. 17, the FDA will be ready for a public meeting to discuss this data. A vaccine could get the thumbs-up shortly thereafter. Either or both the Pfizer and Moderna vaccines may start to become available in mid to late December, though supplies will be limited.
Both use the same novel technology. Instead of injecting a weakened or dead virus, which is a common strategy for vaccines, these products are essentially small pieces of genetic material. When that's injected into a person's arm, it's picked up by cells in the immune system.
The cells read the genetic code and use that to produce a protein that is actually a key fragment of the coronavirus. The body then builds antibodies that latch onto that fragment, so if and when someone encounters the actual coronavirus, the body is primed to fight it off with antibodies.
Though the key action is happening at a cellular level, inoculation can trigger noticeable symptoms, ranging from a sore arm to achiness, or even fever and flu-like symptoms. — Agencies


Clic here to read the story from its source.